Because the infection is a major side effect associated with tocilizumab treatment, the development of an IL-6 inhibitor with a short half-life for use in the treatment of pathogen-induced cytokine storms, such as those cause by sepsis, is desirable. This evidence concerns the gene IL6 and Sepsis.